Propiverine Hydrochloride
PreclinicalSmall molecule
Propiverine Hydrochloride is one of 19 small molecule programs targeting Stress urinary incontinence. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Interstitial Cystitis
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Revia
TevaApproved
Cellcept
RocheApproved
Elavil
AstraZenecaApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Pitocin
RRetrophin
Approved
Botox
AbbVieApproved
Neurontin
VViatris Specialty LLC
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Elmiron
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder3 trials
Stress urinary incontinence1 trial
Interstitial Cystitis1 trial
Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis
Completed·—·N/A·NCT03844581·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Propiverine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLee's Pharmaceutical Limited